REGINA — Thirteen additional uses for existing drugs and two new drugs have been added to the Saskatchewan Cancer Agency's oncology drug formulary.
The new drugs have been recommended by Canada's Drug Agency Pan-Canadian Oncology Drug Review, negotiated through the pan-Canadian Pharmaceutical Alliance and will be available later this spring
According to Saskatchewan Health, the addition of these oncology drugs will benefit more than 450 Saskatchewan residents who are undergoing cancer care in the province.
The Government of Saskatchewan's 2025-26 provincial budget allocated $279 million to the Saskatchewan Cancer Agency.
"Adding these new drugs to the formulary ensures we continue to give the best treatment possible to our patients, providing more treatment options for our patients," Saskatchewan Cancer Agency President and CEO Deb Bulych said.
The drugs being added to the oncology formulary, or having their use expanded, will treat a range of cancers, such as leukemia, lung cancer, breast cancer, prostate cancer and others. The Saskatchewan Cancer Agency will be primarily responsible for the administration of these therapies.
